Spyre Therapeutics, Inc. (SYRE)

NASDAQ: SYRE · IEX Real-Time Price · USD
37.93
+0.93 (2.51%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Total Valuation

SYRE has a market cap or net worth of $990.58 million. The enterprise value is $650.98 million.

Market Cap 990.58M
Enterprise Value 650.98M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, before market open.

Earnings Date May 9, 2024
Ex-Dividend Date n/a

Share Statistics

SYRE has 36.15 million shares outstanding. The number of shares has increased by 104.59% in one year.

Shares Outstanding 36.15M
Shares Change (YoY) +104.59%
Shares Change (QoQ) +60.63%
Owned by Insiders (%) 5.51%
Owned by Institutions (%) 49.50%
Float n/a

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1,118.03
Forward PS n/a
PB Ratio 5.38
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 734.74
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 10.68, with zero debt.

Current Ratio 10.68
Quick Ratio n/a
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -160.40%
Return on Capital (ROIC) -131.67%
Revenue Per Employee $29,533
Profits Per Employee -$11.29M
Employee Count 30
Asset Turnover 0.00
Inventory Turnover n/a

Taxes

Income Tax -26,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +417.96% in the last 52 weeks. The beta is 2.85, so SYRE's price volatility has been higher than the market average.

Beta (1Y) 2.85
52-Week Price Change +417.96%
50-Day Moving Average 30.48
200-Day Moving Average 17.80
Relative Strength Index (RSI) 54.95
Average Volume (30 Days) 481,119

Short Selling Information

The latest short interest is 2.88 million, so 7.96% of the outstanding shares have been sold short.

Short Interest 2.88M
Short Previous Month 2.15M
Short % of Shares Out 7.96%
Short % of Float n/a
Short Ratio (days to cover) 2.51

Income Statement

In the last 12 months, SYRE had revenue of $886,000 and -$338.79 million in losses. Loss per share was -$49.12.

Revenue 886,000
Gross Profit 886,000
Operating Income -242.30M
Pretax Income -338.82M
Net Income -338.79M
EBITDA -337.85M
EBIT -338.82M
Loss Per Share -$49.12
Full Income Statement

Balance Sheet

The company has $339.60 million in cash and no debt, giving a net cash position of $339.60 million or $9.39 per share.

Cash & Cash Equivalents 339.60M
Total Debt n/a
Net Cash 339.60M
Net Cash Per Share $9.39
Equity / Book Value 184.02M
Book Value Per Share 5.09
Working Capital 309.55M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$99.91 million and capital expenditures $475,000, giving a free cash flow of -$99.44 million.

Operating Cash Flow -99.91M
Capital Expenditures 475,000
Free Cash Flow -99.44M
FCF Per Share -$14.42
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -27,347.97% and -38,238.15%.

Gross Margin 100.00%
Operating Margin -27,347.97%
Pretax Margin -38,241.08%
Profit Margin -38,238.15%
EBITDA Margin -38,132.28%
EBIT Margin -38,241.08%
FCF Margin -11,222.91%

Dividends & Yields

SYRE does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -104.59%
Shareholder Yield -104.59%
Earnings Yield -34.20%
FCF Yield -10.04%

Analyst Forecast

The average price target for SYRE is $38.00, which is 0.18% higher than the current price. The consensus rating is "Strong Buy".

Price Target $38.00
Price Target Difference 0.18%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) -33.74%
Stock Forecasts

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 1:25.

Last Split Date Sep 8, 2023
Split Type Reverse
Split Ratio 1:25

Scores

SYRE has an Altman Z-Score of 2.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.8
Piotroski F-Score 2